Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 20 | 2024 | 374 | 6.050 |
Why?
|
| Cell-Free Nucleic Acids | 4 | 2024 | 71 | 3.230 |
Why?
|
| Neoplasms, Second Primary | 5 | 2023 | 252 | 2.480 |
Why?
|
| 5-Methylcytosine | 3 | 2024 | 112 | 1.750 |
Why?
|
| Sarcoma, Ewing | 4 | 2014 | 42 | 1.720 |
Why?
|
| Bone Neoplasms | 6 | 2023 | 322 | 1.600 |
Why?
|
| Osteosarcoma | 2 | 2023 | 158 | 1.040 |
Why?
|
| Child | 17 | 2023 | 6928 | 0.890 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2021 | 19 | 0.830 |
Why?
|
| Child, Preschool | 14 | 2022 | 3613 | 0.810 |
Why?
|
| Prognosis | 11 | 2024 | 3680 | 0.810 |
Why?
|
| Biomarkers, Tumor | 5 | 2022 | 1464 | 0.800 |
Why?
|
| Pediatrics | 3 | 2021 | 344 | 0.780 |
Why?
|
| Research Subjects | 1 | 2021 | 73 | 0.760 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 33 | 0.720 |
Why?
|
| Infant | 12 | 2022 | 3047 | 0.700 |
Why?
|
| Machine Learning | 1 | 2021 | 232 | 0.700 |
Why?
|
| Oncologists | 1 | 2019 | 36 | 0.700 |
Why?
|
| Epigenomics | 1 | 2019 | 100 | 0.680 |
Why?
|
| Fathers | 1 | 2019 | 70 | 0.680 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 298 | 0.670 |
Why?
|
| Neoplasms | 5 | 2023 | 2898 | 0.620 |
Why?
|
| Adolescent | 13 | 2022 | 8982 | 0.560 |
Why?
|
| DNA Methylation | 2 | 2022 | 628 | 0.560 |
Why?
|
| Survivors | 2 | 2016 | 226 | 0.550 |
Why?
|
| Humans | 37 | 2024 | 86645 | 0.530 |
Why?
|
| Young Adult | 11 | 2022 | 5976 | 0.490 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2022 | 1197 | 0.490 |
Why?
|
| Hypoxia | 3 | 2023 | 641 | 0.470 |
Why?
|
| Radiation Injuries | 1 | 2014 | 155 | 0.460 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2011 | 127 | 0.460 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 196 | 0.460 |
Why?
|
| Rheumatic Diseases | 1 | 2013 | 20 | 0.440 |
Why?
|
| Annexin A5 | 1 | 2012 | 20 | 0.440 |
Why?
|
| Transition to Adult Care | 1 | 2013 | 22 | 0.440 |
Why?
|
| Medical Informatics | 1 | 2013 | 47 | 0.430 |
Why?
|
| Radiotherapy | 1 | 2014 | 328 | 0.430 |
Why?
|
| Genomics | 2 | 2022 | 720 | 0.430 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2011 | 6 | 0.420 |
Why?
|
| Patient Preference | 1 | 2013 | 105 | 0.410 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 532 | 0.390 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 763 | 0.380 |
Why?
|
| N-Myc Proto-Oncogene Protein | 2 | 2022 | 36 | 0.370 |
Why?
|
| Apoptosis | 3 | 2023 | 1683 | 0.370 |
Why?
|
| Male | 15 | 2021 | 40967 | 0.370 |
Why?
|
| Aging | 1 | 2014 | 691 | 0.350 |
Why?
|
| Female | 18 | 2023 | 44534 | 0.350 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2016 | 860 | 0.320 |
Why?
|
| Models, Biological | 2 | 2016 | 1749 | 0.320 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 859 | 0.290 |
Why?
|
| Adult | 10 | 2022 | 25648 | 0.290 |
Why?
|
| Paraffin Embedding | 2 | 2016 | 78 | 0.260 |
Why?
|
| Infant, Newborn | 5 | 2022 | 2379 | 0.260 |
Why?
|
| Medical Oncology | 2 | 2021 | 359 | 0.260 |
Why?
|
| Risk Factors | 4 | 2021 | 5417 | 0.240 |
Why?
|
| Signal Transduction | 1 | 2014 | 3241 | 0.240 |
Why?
|
| Disease-Free Survival | 3 | 2022 | 1204 | 0.230 |
Why?
|
| Cohort Studies | 3 | 2021 | 2767 | 0.230 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2023 | 24 | 0.220 |
Why?
|
| Induction Chemotherapy | 2 | 2022 | 147 | 0.220 |
Why?
|
| SEER Program | 2 | 2014 | 190 | 0.220 |
Why?
|
| Teratoma | 1 | 2023 | 50 | 0.220 |
Why?
|
| Cell Line, Tumor | 5 | 2023 | 2426 | 0.220 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 47 | 0.220 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2023 | 104 | 0.210 |
Why?
|
| DNA, Neoplasm | 1 | 2023 | 265 | 0.210 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2022 | 42 | 0.210 |
Why?
|
| Mixed Function Oxygenases | 1 | 2022 | 68 | 0.210 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2023 | 456 | 0.210 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 1 | 2023 | 40 | 0.210 |
Why?
|
| Gene Amplification | 2 | 2023 | 131 | 0.210 |
Why?
|
| Histones | 1 | 2024 | 311 | 0.200 |
Why?
|
| Survival Rate | 3 | 2020 | 1863 | 0.200 |
Why?
|
| Methyltransferases | 1 | 2023 | 182 | 0.200 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 76 | 0.200 |
Why?
|
| Research Report | 1 | 2021 | 44 | 0.200 |
Why?
|
| Radionuclide Imaging | 1 | 2021 | 220 | 0.200 |
Why?
|
| Incidence | 2 | 2016 | 1577 | 0.200 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 301 | 0.190 |
Why?
|
| Glioma | 1 | 2023 | 285 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2021 | 2271 | 0.190 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 56 | 0.190 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 1939 | 0.190 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 1686 | 0.180 |
Why?
|
| Parenchymal Tissue | 1 | 2020 | 6 | 0.180 |
Why?
|
| Intergenerational Relations | 1 | 2019 | 5 | 0.180 |
Why?
|
| Bayes Theorem | 1 | 2021 | 361 | 0.180 |
Why?
|
| Pleura | 1 | 2020 | 30 | 0.180 |
Why?
|
| Back Pain | 1 | 2019 | 42 | 0.180 |
Why?
|
| Family Relations | 1 | 2019 | 35 | 0.180 |
Why?
|
| Age Factors | 2 | 2021 | 1851 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 645 | 0.170 |
Why?
|
| Naphthyridines | 1 | 2019 | 53 | 0.160 |
Why?
|
| Survival Analysis | 1 | 2021 | 1538 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1313 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 2438 | 0.150 |
Why?
|
| Serum Albumin, Bovine | 1 | 2016 | 45 | 0.150 |
Why?
|
| Retrospective Studies | 3 | 2023 | 8491 | 0.150 |
Why?
|
| Palmitic Acid | 1 | 2016 | 26 | 0.150 |
Why?
|
| Osteonectin | 1 | 2016 | 22 | 0.150 |
Why?
|
| Databases, Nucleic Acid | 1 | 2016 | 41 | 0.140 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2020 | 235 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 744 | 0.140 |
Why?
|
| Tissue Fixation | 1 | 2016 | 40 | 0.140 |
Why?
|
| Formaldehyde | 1 | 2016 | 52 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 865 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 196 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 1056 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 878 | 0.130 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 294 | 0.130 |
Why?
|
| DNA Repair | 1 | 2016 | 356 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2022 | 7993 | 0.120 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 188 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 689 | 0.120 |
Why?
|
| Radiation Dosage | 1 | 2014 | 227 | 0.110 |
Why?
|
| Computational Biology | 1 | 2016 | 528 | 0.110 |
Why?
|
| Reference Values | 1 | 2014 | 674 | 0.110 |
Why?
|
| Consumer Health Information | 1 | 2013 | 13 | 0.110 |
Why?
|
| Focus Groups | 1 | 2013 | 155 | 0.110 |
Why?
|
| Transcriptome | 1 | 2016 | 580 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2016 | 2262 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 3640 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2013 | 256 | 0.100 |
Why?
|
| Self Care | 1 | 2013 | 164 | 0.100 |
Why?
|
| Social Support | 1 | 2013 | 193 | 0.100 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2011 | 9 | 0.100 |
Why?
|
| Sex Factors | 1 | 2014 | 1054 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1384 | 0.100 |
Why?
|
| Heterografts | 2 | 2023 | 98 | 0.100 |
Why?
|
| Patient Participation | 1 | 2013 | 216 | 0.100 |
Why?
|
| Disease Management | 1 | 2013 | 327 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2705 | 0.090 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 486 | 0.090 |
Why?
|
| Computer Simulation | 1 | 2014 | 1078 | 0.090 |
Why?
|
| Bone and Bones | 1 | 2011 | 265 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2013 | 971 | 0.090 |
Why?
|
| Cell Hypoxia | 2 | 2022 | 164 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2818 | 0.080 |
Why?
|
| International Cooperation | 2 | 2020 | 127 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 1621 | 0.080 |
Why?
|
| Cell Movement | 2 | 2022 | 758 | 0.070 |
Why?
|
| Middle Aged | 2 | 2014 | 25028 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2022 | 4213 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2019 | 1578 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 6509 | 0.050 |
Why?
|
| HeLa Cells | 1 | 2023 | 498 | 0.050 |
Why?
|
| Mice | 3 | 2023 | 11352 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 162 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 331 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2023 | 790 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 407 | 0.050 |
Why?
|
| Mitotic Index | 1 | 2020 | 20 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2022 | 266 | 0.050 |
Why?
|
| Mitosis | 1 | 2020 | 153 | 0.050 |
Why?
|
| Cough | 1 | 2020 | 54 | 0.040 |
Why?
|
| Dyspnea | 1 | 2020 | 73 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 683 | 0.040 |
Why?
|
| Fibrosis | 1 | 2020 | 203 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 357 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2021 | 395 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 63 | 0.040 |
Why?
|
| Animals | 3 | 2023 | 26582 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 677 | 0.030 |
Why?
|
| Aged | 1 | 2012 | 18415 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 71 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 310 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 130 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2016 | 342 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 387 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 174 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 969 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1805 | 0.030 |
Why?
|
| Mutation | 1 | 2023 | 3968 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1673 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 1621 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 2357 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 5210 | 0.020 |
Why?
|